StemCells, Inc. , a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, announced today that it has transplanted the first subject in its Phase II PathwayA Study assessing the efficacy of its proprietary HuCNS-SCA platform technology for the treatment of cervical spinal cord injury . The transplant was performed at the University of Miami Hospital within the Miller School of Medicine, home to The Miami Project to Cure Paralysis, one of the world's most comprehensive spinal cord injury research centers dedicated to finding effective treatments for paralysis.
http://ift.tt/1wmkrbK
http://ift.tt/1wmkrbK
No comments:
Post a Comment